TX-RIVERSAND
7.10.2020 08:02:14 CEST | Business Wire | Press release
Digital Consulting firm ADROSONIC, today announced a strategic partnership with Riversand, a US-based multidomain Master Data Management (MDM) and Product Information Management (PIM) solution provider, to develop and deliver cloud-native MDM and PIM solutions with rapid deployment to Insurance markets, specifically in the UK and the USA.
Recognised as the only Visionary by Gartner in its Magic Quadrant for Master Data Management, Riversand has disrupted the traditional PIM and MDM markets. ADROSONIC will leverage its Insurance domain knowledge and success in the UK Insurance market with Riversand’s technology to create strategic and competitively advantageous solutions for its clients. Beyond Insurance, ADROSONIC’s depth includes other domains such as Manufacturing.
“ADROSONIC's strong domain knowledge within Insurance, Manufacturing and Social Welfare organisations is unparalleled in Europe and the US,” said Jasleen Ahluwalia, vice president of Business Development at Riversand. “Their extensive experience in delivering multiple complex data projects, combined with their expertise in Quality Assurance and Automation and fast implementation, will benefit customers and help them realize better competitive value.”
“Riversand’s intuitive, 100 percent cloud-native MDM and PIM solution caters to both B2B and B2C markets. When coupled with ADROSONIC’s domain knowledge and expertise in handling complex data projects and comprehensive delivery methodology, this promises cost efficiency and quicker time-to-value, thus lowering the total cost of ownership for the business,” said Mr. Mayank, CEO and MD at ADROSONIC. “Organisations going through a digital transformation journey are looking for MDM solutions that can be integrated with their cloud-first strategy and our combined efforts fit perfectly with their needs.”
About Riversand
Riversand’s cloud-native master data management solutions are designed to support customers’ digital transformation journeys through improved business agility, faster adoption and improved collaboration across the enterprise. Driving data to experiences, Riversand has a vision of helping companies know their customers better, move products faster, automate processes, mitigate risk and run their businesses smarter. Visit https://Riversand.com for more information and follow us @RiversandMDM on Twitter and Riversand on LinkedIn.
About ADROSONIC
ADROSONIC is an innovative, business-focused Digital consulting firm empowering organisations with a complete framework of IT Solutions and Services. A trusted partner for both service and product-based companies, ADROSONIC has a global presence with offices in India, UK and the USA. Possessing competencies in the fields of Robotic Process Automation, Data Analytics, CRM services, Application Services, Digital Quality Assurance and Software Testing, ADROSONIC strives to pave the Digital Roadmap for emerging and traditional business organisations. Reach out to us at www.adrosonic.com and follow us on @adrosonic on Twitter and ADROSONIC on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201006006153/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
Seoul Viosys Eyes the $60 Billion AI Data Center Optical Communication Market with Opto Semiconductors27.4.2026 15:00:00 CEST | Press release
Joint Development Talks with Global Optical Communications companiesExpanding Partnerships to Provide Total Transceiver Solution1,800 Patents Secured for High-Performance Optical Communications Seoul Viosys (KOSDAQ: 092190), a company specializing in opto-semiconductor devices, is accelerating its entry into the next-generation photonics market supported by its proprietary “No-wire” and “No-package” fundamental patents—essential technologies for micrometer (μm)-scale miniaturization of opto-semiconductors—as well as its competitiveness in VCSEL technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426926495/en/ Seoul Viosys Optoelectronic Semiconductor Structure Subject to a Permanent U.S. Injunction in February 2026, Covering Similar Products and Employees (Image: Seoul Viosys) As the rapid expansion of AI drives a paradigm shift in data centers from copper-based to optical-based architectures, the company is streng
vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 14:51:00 CEST | Press release
Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom